Content Hub
NEWLY ADDED!
Strength, Weakness, Opportunity and Threat Analysis of Enhertu (trastuzumab deruxtecan), a HER2-targeting antibody-drug conjugate (ADC) bearing a topoisomerase inhibitor payload; approved for unresectable or metastatic HER2-positive breast cancer patients.
Hanson Wade
NEWLY ADDED!
Strength, Weakness, Opportunity and Threat Analysis of Trodelvy (sacituzumab govitecan-hziy), a Trop-2-directed antibody-drug conjugate (ADC) bearing a topoisomerase inhibitor payload; approved for patients with relapsed or refractory metastatic triple-negative breast cancer (TNBC).
Hanson Wade
NEWLY ADDED!
CAR-TCR Presentation
CAR T Cells for Solid Tumours, To Do List
Francesco M. Marincola, Chief Research Officer, Refuge Biotechnologies
NEWLY ADDED!
CAR-TCR Presentation
Identification of Novel Shared Targets for Solid Tumors
Hans-Peter Gerber, Ph.D. SVP & CSO,3T Bioscience